Immunome, Inc. and Zentalis Pharmaceuticals, Inc. announced that they have entered into an exclusive, worldwide license agreement under which Immunome has licensed from Zentalis ZPC-21, a preclinical ROR1 antibody-drug Conjugate (ADC) with best-in-class potential on track for IND submission in first quarter of 2025, and Zentalis' proprietary ADC platform technology. Under the terms of the deal, Zentalis will receive an up-front payment of $35 million in cash and Immunome common stock. Zentalis will be eligible to receive up to $275 million of milestone payments for ZPC-21 and the platform technology in addition to mid-to-high single-digit royalties.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.22 USD | -0.84% | +2.82% | +32.90% |
May. 21 | Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing | MT |
May. 20 | Immunome Completes Purchase of Antibodies From Atreca | MT |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
14.22 USD | -0.84% | +2.82% | 852M | ||
11.27 USD | -0.09% | -6.63% | 800M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+32.90% | 852M | |
+12.30% | 118B | |
+12.15% | 106B | |
-8.14% | 23.4B | |
-1.25% | 21.78B | |
-9.07% | 18.09B | |
-41.25% | 16.72B | |
-15.33% | 15.97B | |
+5.80% | 14.03B | |
+28.03% | 11.67B |
- Stock Market
- Equities
- IMNM Stock
- News Immunome, Inc.
- Immunome, Inc. and Zentalis Pharmaceuticals, Inc. Enter into an Exclusive, Worldwide License Agreement Under Which Immunome Has Licensed from Zentalis ZPC-21, A Preclinical Ror1 Antibody-Drug Conjugate